NE NEWS SERVICE
AHMEDABAD, JUNE 1
Continuing its saga of success in treating COVID-19 patients, on Monday, May 31st, city-based CIMS Hospital administered monoclonal antibodies cocktail therapy for COVID-19 treatment becoming one of the first hospitals in the city to commence this treatment, says a senior doctor.
“The monoclonal antibodies cocktail treatment was launched in India just last week for treating mild COVID-19 patients. A 38-year-old diabetic male patient with COVID-19 symptoms was administered the monoclonal antibodies cocktail treatment with Casirivimab and Imdevimab. We are the first hospital in Ahmedabad to begin this treatment,” said Dr. Surabhi Madan, Head of Department, Infectious Diseases Department, CIMS hospital.
CIMS’ saga of success: Airlifted from Uttarakhand, Mumbai man beats COVID after 55 days
According to Dr. Madan, the cocktail treatment is recommended only in the early stages of the COVID-19 infection and for high-risk group patients. It is the same treatment which former President Trump received in the year 2020.
“The patient we administered the combination medication today has diabetes, and hence belongs to the high-risk group. The high mortality in young males during the second wave has been a grave concern for the medical fraternity. This medication is not recommended for Covid-19 patients who have moderate or severe disease with hypoxia,” she stressed.
According to the Covid Care Team of CIMS Hospital, the monoclonal antibodies cocktail treatment can be given to the high risk group of patients in the early stages of the Covid-19 infection, displaying very mild or mild Covid-19 symptoms, and not having any oxygen requirement.
The combination drugs aim to block the entry of the SARS-CoV-2 into the cells and prevent progression and worsening of the infection to moderate and severe Covid-19, the team explained.
The high-risk subgroups, including patients above 60, those suffering from chronic kidney diseases, lung diseases, or liver diseases, cardiovascular diseases, transplant & cancers patients, etc. who are more likely to develop a severe form Covid-19, but are in the early stages of the infection and have early symptoms should be ideally considered for this medication, the team added.
The Covid Care Team was specially thankful to CIMS management for pioneering and facilitating the commencement of the monoclonal antibodies cocktail treatment with Casirivimab and Imdevimab in Ahmedabad.
CIMS Hospital has been in the forefront of Covid care treatment and has treated more than 5000 COVID-19 patient with a very high success rate and emerged as the Centre of Excellence for Covid Care.
